Archive

ESMO 2014 Report: FOLFIRI plus cetuximab in patients with liver-limited or non-liverlimited RAS wild-type metastatic disease

by Esther Drain:  A sub-group analysis of the CRYSTAL study.  In the CRYSTAL study, adding cetuximab (cet) to first-line chemotherapy (CT) improved clinical outcome in patients (pts) with RAS… read more.

ESMO 2014 Report: Special symposium on ‘Advances in precision medicine of metastatic colorectal cancer’

by Denys Wheatley: There is some irony in the title of this symposium because medicine should always be as precise as it can, and advances are expected that… read more.

ESMO 2014: Video Interview with Professors Heinz-Joseph Lenz and Volker Heinemann: Following ESMO, what should be the sequence of treatment for RAS wt mCRC? Click on the image to hear interview.

Professor Lenz gives his opinions following the presentation of data from FIRE 3 and CALGB/SWOG 80405 at ESMO 2014.

ESMO 2014 Report: Adolescent and young adult cancer patients

Engagement of patients and understanding of early death in this group by Denys Wheatley. (1) When and why do teenage and young adult oncology patients die early in… read more.

ESMO 2014 Report: Proton beam therapy: Emperor’s new clothes

by Denis Wheatley:  In her introduction, Yolane Lievens (Belgium) explained that when we have to defer from making comment because of the need to be discrete (the Emperor… read more.

ESMO 2014 Report: Reclassifying cancer through genomics

Keynote lecture: Professor Sir Mike Stratton (Cambridge/Hinxton, UK) by Denys Wheatley.  On the thesis that the genetic understanding of cancer is fundamental to classifying and hence treating patients… read more.

ESMO 2014: Video Interview with Professor Richard Adams (Cardiff) and Dr Harpreet Wasan (London): What are the barriers to optimising the treatment of mCRC in the UK, and are we overcoming them? Click on the image to hear interview.

ESMO 2014 Report: Video interview with Professor Volker Heinemann (Munich) and other delegate views.

Click ‘Read More’ for the new data delegate views on whether early tumour shrinkage is now an accepted marker in mCRC.

ESMO 2014 Report: How to integrate genome sequencing data in oncology

by Denys Wheatley: Chaired by Atsushi Ohtsu and Jean-Yves Douillard, the first speaker Dr Kato (Japan) addressed the issue of the quest for different mutations in the hope… read more.

ESMO 2014: Poster Session: REBECCA

by Denys Wheatley: A large cohort study of Regorafenib (REG) in the real-life setting in patients previously treated for metastatic colorectal cancer

ESMO 2014: Poster Session: MOSAIC study – Actualization of overall survival with a 10-year follow up and evaluation of BRAF (GREGOR investigators)

by Denys Wheatley: The session dealt primarily with the advanced (stage 2 and 3) colon cancer patients who had undergone resection, in a study discussed by Thiery Andre… read more.

ESMO 2014: Video Interview with Professor Dirk Arnold (Germany): Should patients be stratified according to their RAS status before 1st line treatment is initiated? Click on the image to hear interview.